CY1117559T1 - Ενωση ινδολιου και φαρμακευτικη χρηση αυτου - Google Patents

Ενωση ινδολιου και φαρμακευτικη χρηση αυτου

Info

Publication number
CY1117559T1
CY1117559T1 CY20161100462T CY161100462T CY1117559T1 CY 1117559 T1 CY1117559 T1 CY 1117559T1 CY 20161100462 T CY20161100462 T CY 20161100462T CY 161100462 T CY161100462 T CY 161100462T CY 1117559 T1 CY1117559 T1 CY 1117559T1
Authority
CY
Cyprus
Prior art keywords
indolium
union
pharmaceutical use
diseases
prophylaxis
Prior art date
Application number
CY20161100462T
Other languages
English (en)
Inventor
Teruhiko Inoue
Tetsudo Kaya
Shinichi Kikuchi
Koji Matsumura
Ritsuki Masuo
Motoya Suzuki
Michihide Maekawa
Original Assignee
Japan Tobacco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco, Inc. filed Critical Japan Tobacco, Inc.
Publication of CY1117559T1 publication Critical patent/CY1117559T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Παρεχόμενος είναι ένας παράγων για τη θεραπεία ή την προφύλαξη φλεγμονωδών ασθενειών, αλλεργικών ασθενειών, αυτοάνοσων ασθενειών, απόρριψης μεταμόσχευσης ή των παρομοίων. Μία ένωση που αντιπροσωπεύεται με τον παρακάτω τύπο [I] ή φαρμακευτικώς αποδεκτό άλας αυτής, ή διαλύτωμα αυτής: όπου έκαστο σύμβολο είναι όπως περιγράφεται στην προδιαγραφή.
CY20161100462T 2009-11-25 2016-05-26 Ενωση ινδολιου και φαρμακευτικη χρηση αυτου CY1117559T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009268040 2009-11-25
EP10833248.7A EP2505586B1 (en) 2009-11-25 2010-11-25 Indole compound and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
CY1117559T1 true CY1117559T1 (el) 2017-04-26

Family

ID=44066507

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100462T CY1117559T1 (el) 2009-11-25 2016-05-26 Ενωση ινδολιου και φαρμακευτικη χρηση αυτου

Country Status (31)

Country Link
US (6) US8299070B2 (el)
EP (3) EP3766877A1 (el)
JP (6) JP5734628B2 (el)
KR (1) KR101766502B1 (el)
CN (1) CN102712624B (el)
AR (1) AR079164A1 (el)
AU (1) AU2010323579C1 (el)
BR (1) BR112012012529B1 (el)
CA (1) CA2781660C (el)
CL (1) CL2012001328A1 (el)
CO (1) CO6541645A2 (el)
CY (1) CY1117559T1 (el)
DK (1) DK2505586T3 (el)
ES (1) ES2572935T3 (el)
HK (1) HK1174025A1 (el)
HR (1) HRP20160579T1 (el)
HU (1) HUE028016T2 (el)
IL (1) IL220009A (el)
ME (1) ME02447B (el)
MX (1) MX2012006017A (el)
MY (1) MY161095A (el)
NZ (1) NZ600840A (el)
PE (1) PE20121358A1 (el)
PL (1) PL2505586T3 (el)
PT (1) PT2505586E (el)
RS (1) RS54910B1 (el)
RU (1) RU2556216C2 (el)
SI (1) SI2505586T1 (el)
SM (1) SMT201600258B (el)
TW (1) TWI491591B (el)
WO (1) WO2011065402A1 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
EP2877598A1 (en) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
PE20151604A1 (es) * 2012-11-02 2015-11-04 Pharmacyclics Llc Terapia adyuvante con inhibidores de quinasa de la familia tec
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CN103804291A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103804361A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800337A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
CN103800340A (zh) * 2012-11-09 2014-05-21 韩冰 一类治疗青光眼的化合物及其用途
CN103804363A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804272A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN103804302A (zh) * 2012-11-14 2014-05-21 杨育新 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103804351A (zh) * 2012-11-14 2014-05-21 韩冰 一类具有神经保护作用的化合物及其用途
CN104628657A (zh) * 2013-11-06 2015-05-20 韩冰 一类治疗缺血性脑损伤的化合物及其用途
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
AR099936A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
JP6596417B2 (ja) * 2014-07-04 2019-10-23 日本たばこ産業株式会社 インドール化合物の製造方法
WO2016010108A1 (ja) * 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
CN104356086A (zh) * 2014-11-28 2015-02-18 湖南科技大学 一种适于工业生产3-吗啉酮的制备方法
US12011448B2 (en) 2018-05-25 2024-06-18 Japan Tobacco Inc. Therapeutic or preventing agent for nephrotic syndrome including indole compound
EP3804726A4 (en) * 2018-05-25 2022-03-16 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS CONTAINING AN INDOLE COMPOUND
BR112020022377A2 (pt) * 2018-05-25 2021-02-02 Japan Tobacco, Inc. método para o tratamento da dor ou cistite intersticial usando um composto indol
EP4077316A1 (en) 2019-12-20 2022-10-26 Pfizer Inc. Benzimidazole derivatives
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
WO2022130175A1 (en) * 2020-12-15 2022-06-23 Pfizer Inc. Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease
JP2023552863A (ja) * 2020-12-15 2023-12-19 ファイザー・インク ベンゾイミダゾール誘導体および皮膚疾患の処置のためのｉｔｋの阻害剤としてのそれらの使用
EP4334302A1 (en) * 2021-05-03 2024-03-13 Nurix Therapeutics, Inc. Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
MX2023013001A (es) * 2021-05-03 2024-01-17 Nurix Therapeutics Inc Compuestos para inhibir o degradar itk, composiciones que comprenden los mismos, metodos para su elaboracion y metodos para su uso.
TW202315618A (zh) * 2021-06-11 2023-04-16 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物
WO2023069514A2 (en) * 2021-10-19 2023-04-27 Nurix Therapeutics, Inc. Bifunctional compounds for degrading itk via ubiquitin proteosome pathway

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US953411A (en) * 1908-09-02 1910-03-29 Erastus De Moulin Trick weight-lifting machine.
AU2002334217B2 (en) * 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
MXPA04006614A (es) * 2002-01-07 2004-10-04 Eisai Co Ltd Deazapurinas y usos de las mismas.
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2004272507B2 (en) * 2003-09-08 2011-05-12 Aventis Pharmaceuticals Inc. Thienopyrazoles
CN101163675A (zh) * 2005-04-19 2008-04-16 协和发酵工业株式会社 含氮杂环化合物
EP1968580A2 (en) 2005-12-20 2008-09-17 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
US8604031B2 (en) * 2006-05-18 2013-12-10 Mannkind Corporation Intracellular kinase inhibitors
EP2108642A1 (en) * 2006-10-17 2009-10-14 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
US8362066B2 (en) 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP2009268040A (ja) 2008-04-23 2009-11-12 Teruhiko Daiho ループアンテナ装置
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof

Also Published As

Publication number Publication date
WO2011065402A1 (ja) 2011-06-03
US20200255408A1 (en) 2020-08-13
SI2505586T1 (sl) 2016-08-31
ME02447B (me) 2016-09-20
US20210284627A1 (en) 2021-09-16
TW201124378A (en) 2011-07-16
RS54910B1 (sr) 2016-10-31
CA2781660C (en) 2018-06-26
EP2505586A4 (en) 2013-05-15
PL2505586T3 (pl) 2016-12-30
KR101766502B1 (ko) 2017-08-08
CN102712624B (zh) 2014-06-04
IL220009A (en) 2017-08-31
AU2010323579C1 (en) 2016-11-03
HRP20160579T1 (hr) 2016-07-29
JP2021091718A (ja) 2021-06-17
RU2556216C2 (ru) 2015-07-10
EP3059234A1 (en) 2016-08-24
PT2505586E (pt) 2016-06-03
AR079164A1 (es) 2011-12-28
CN102712624A (zh) 2012-10-03
US20130116240A1 (en) 2013-05-09
JP2017039761A (ja) 2017-02-23
EP2505586A1 (en) 2012-10-03
JP2018158935A (ja) 2018-10-11
CO6541645A2 (es) 2012-10-16
TWI491591B (zh) 2015-07-11
JP5734628B2 (ja) 2015-06-17
US20110306599A1 (en) 2011-12-15
PE20121358A1 (es) 2012-10-23
IL220009A0 (en) 2012-07-31
JP2011132222A (ja) 2011-07-07
US20180362506A1 (en) 2018-12-20
US8299070B2 (en) 2012-10-30
BR112012012529B1 (pt) 2021-10-26
US20170267662A1 (en) 2017-09-21
MX2012006017A (es) 2012-06-25
JP2020079276A (ja) 2020-05-28
ES2572935T3 (es) 2016-06-03
JP2015172051A (ja) 2015-10-01
RU2012126129A (ru) 2013-12-27
HK1174025A1 (zh) 2013-05-31
AU2010323579A1 (en) 2012-07-19
MY161095A (en) 2017-04-14
NZ600840A (en) 2014-01-31
SMT201600258B (it) 2016-08-31
BR112012012529A2 (pt) 2016-05-03
EP3766877A1 (en) 2021-01-20
KR20120096540A (ko) 2012-08-30
EP2505586B1 (en) 2016-03-02
CA2781660A1 (en) 2011-06-03
DK2505586T3 (en) 2016-05-30
AU2010323579B2 (en) 2016-05-19
CL2012001328A1 (es) 2012-10-05
HUE028016T2 (en) 2016-11-28

Similar Documents

Publication Publication Date Title
CY1117559T1 (el) Ενωση ινδολιου και φαρμακευτικη χρηση αυτου
CY1123626T1 (el) Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
CY2020032I2 (el) Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια
CY1125290T1 (el) Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1121631T1 (el) Ενωση πυραζολης και φαρμακευτικη χρηση εξ αυτης
CY1118340T1 (el) Αναστολεις κινασης
CR20160035A (es) Inhibidores de bromodominios
CY1118747T1 (el) Ενωση σπειρο-δακτυλιου που περιεχει αζωτο και ιατρικη χρηση αυτης
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
EA030189B8 (ru) Аналоги 2'-хлоронуклеозидов для инфекции вгс
ES2898695T8 (es) Derivados de benzoxaborol para el tratamiento de infecciones bacterianas
UY35395A (es) Inhibidores de bromodominios tetracíclicos
CO6680717A2 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
EA201492204A1 (ru) Нуклеозиды на основе урацила и спирооксетана
CY1116007T1 (el) Ενωση ιμιδαζο[4,5-c]κινολιν-2-ονης και χρηση της ως διπλος αναστολεας της ρ13 κινασης/mtor
CO6660502A2 (es) Compuestos macrocíclicos como inhibidores de quinasa trk
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
DOP2016000266A (es) CROMENO Y 1,1a,2,7b–TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
EA201591024A1 (ru) Димерные соединения